Keros Therapeutics (KROS) Stock Forecast, Price Target & Predictions
KROS Stock Forecast
Keros Therapeutics stock forecast is as follows: an average price target of $105.00 (represents a 84.28% upside from KROS’s last price of $56.98) and a rating consensus of 'Buy', based on 3 wall street analysts offering a 1-year stock forecast.
KROS Price Target
The average price target for Keros Therapeutics (KROS) is $105.00 based on 1-year price targets from 3 Wall Street analysts in the past 3 months, with a price target range of $105.00 to $105.00. This represents a potential 84.28% upside from KROS's last price of $56.98.
KROS Analyst Ratings
According to 3 Wall Street analysts, Keros Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for KROS stock is 0 'Strong Buy' (0.00%), 3 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Keros Therapeutics Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Jun 18, 2024 | Joseph Catanzaro | Piper Sandler | $105.00 | $44.65 | 135.16% | 84.28% |
| Dec 13, 2022 | - | BTIG | $105.00 | $49.98 | 110.08% | 84.28% |
| Jul 27, 2022 | Julian Harrison | BTIG | $80.00 | $31.79 | 151.65% | 40.40% |
| May 18, 2022 | Joseph Catanzaro | Piper Sandler | $120.00 | $39.92 | 200.60% | 110.60% |
The latest Keros Therapeutics stock forecast, released on Jun 18, 2024 by Joseph Catanzaro from Piper Sandler, set a price target of $105.00, which represents a 135.16% increase from the stock price at the time of the forecast ($44.65), and a 84.28% increase from KROS last price ($56.98).
Keros Therapeutics Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 1 | 1 |
| Avg Price Target | - | $105.00 | $105.00 |
| Last Closing Price | $56.98 | $56.98 | $56.98 |
| Upside/Downside | -100.00% | 84.28% | 84.28% |
In the current month, the average price target of Keros Therapeutics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Keros Therapeutics's last price of $56.98. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Jun 24, 2024 | Oppenheimer | - | Outperform | Initialise |
| Jun 18, 2024 | Piper Sandler | Overweight | Overweight | Hold |
| Dec 13, 2022 | BTIG | Buy | Buy | Hold |
| Oct 10, 2022 | Piper Sandler | Overweight | Overweight | Hold |
| Jul 27, 2022 | BTIG | - | Buy | Initialise |
Keros Therapeutics's last stock rating was published by Oppenheimer on Jun 24, 2024. The company Initialise its KROS rating from "null" to "Outperform".
Keros Therapeutics Financial Forecast
Keros Therapeutics Revenue Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Jun 23 | Mar 23 | Dec 22 | Mar 22 | Jun 21 | Sep 20 | Mar 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $100.00K | - | - |
| Avg Forecast | $6.54K | $7.78K | $9.25K | $11.00K | $-33.33K | $15.56K | $18.50K | $22.00K | $3.33M | $31.11K | $37.00K | $83.00K | $143.00K | $216.67K | $325.00K | $1.20M | $6.00M | $100.00K | $62.50K | $83.33K |
| High Forecast | $6.54K | $7.78K | $9.25K | $11.00K | $-33.33K | $15.56K | $18.50K | $22.00K | $3.33M | $31.11K | $37.00K | $83.00K | $143.00K | $216.67K | $325.00K | $1.20M | $6.00M | $120.00K | $62.50K | $83.33K |
| Low Forecast | $6.54K | $7.78K | $9.25K | $11.00K | $-33.33K | $15.56K | $18.50K | $22.00K | $3.33M | $31.11K | $37.00K | $83.00K | $143.00K | $216.67K | $325.00K | $1.20M | $6.00M | $80.00K | $62.50K | $83.33K |
| # Analysts | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 5 | 4 | 4 | 2 | 10 | 4 | 4 | 3 | 17 | 19 | 16 | 9 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.00% | - | - |
Keros Therapeutics's average Quarter revenue forecast for Mar 22 based on 17 analysts is $6.00M, with a low forecast of $6.00M, and a high forecast of $6.00M. KROS's average Quarter revenue forecast represents a 5900.00% increase compared to the company's last Quarter revenue of $100.00K (Jun 21).
Keros Therapeutics EBITDA Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Jun 23 | Mar 23 | Dec 22 | Mar 22 | Jun 21 | Sep 20 | Mar 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 5 | 4 | 4 | 2 | 10 | 4 | 4 | 3 | 17 | 19 | 16 | 9 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | $-37.31M | $-35.64M | $-29.72M | $-24.07M | $-15.53M | $-11.96M | $-12.00M |
| Avg Forecast | $-1.28K | $-1.52K | $-1.81K | $-2.15K | $6.53K | $-3.05K | $-3.62K | $-4.31K | $-653.13K | $-6.10K | $-7.25K | $-16.26K | $-28.02K | $-42.45K | $-63.68K | $-235.13K | $-19.87M | $-15.29M | $-12.25K | $-110.99M |
| High Forecast | $-1.28K | $-1.52K | $-1.81K | $-2.15K | $6.53K | $-3.05K | $-3.62K | $-4.31K | $-653.13K | $-6.10K | $-7.25K | $-16.26K | $-28.02K | $-42.45K | $-63.68K | $-235.13K | $-15.90M | $-12.24M | $-12.25K | $-88.79M |
| Low Forecast | $-1.28K | $-1.52K | $-1.81K | $-2.15K | $6.53K | $-3.05K | $-3.62K | $-4.31K | $-653.13K | $-6.10K | $-7.25K | $-16.26K | $-28.02K | $-42.45K | $-63.68K | $-235.13K | $-23.85M | $-18.35M | $-12.25K | $-133.18M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 878.95% | 559.63% | 126.39% | 1.21% | 1.02% | 976.81% | 0.11% |
undefined analysts predict KROS's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Keros Therapeutics's previous annual EBITDA (undefined) of $NaN.
Keros Therapeutics Net Income Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Jun 23 | Mar 23 | Dec 22 | Mar 22 | Jun 21 | Sep 20 | Mar 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 5 | 4 | 4 | 2 | 10 | 4 | 4 | 3 | 17 | 19 | 16 | 9 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | - | $-37.51M | $-32.74M | $-29.72M | $-24.19M | $-15.62M | $-12.04M | $-11.89M |
| Avg Forecast | $-36.28M | $-35.93M | $-35.61M | $-35.28M | $-45.63M | $-45.19M | $-46.95M | $-45.80M | $-44.04M | $-46.00M | $-45.43M | $-39.26M | $-41.40M | $-48.34M | $-40.54M | $-39.61M | $-19.97M | $-15.39M | $-17.93M | $-126.41M |
| High Forecast | $-36.28M | $-35.93M | $-35.61M | $-35.28M | $-45.63M | $-45.19M | $-46.95M | $-45.80M | $-44.04M | $-40.52M | $-45.43M | $-39.26M | $-37.80M | $-48.34M | $-40.54M | $-39.61M | $-15.97M | $-12.31M | $-17.93M | $-101.13M |
| Low Forecast | $-36.28M | $-35.93M | $-35.61M | $-35.28M | $-45.63M | $-45.19M | $-46.95M | $-45.80M | $-44.04M | $-53.67M | $-45.43M | $-39.26M | $-45.90M | $-48.34M | $-40.54M | $-39.61M | $-23.96M | $-18.46M | $-17.93M | $-151.69M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.78% | 0.81% | 0.75% | 1.21% | 1.02% | 0.67% | 0.09% |
Keros Therapeutics's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. KROS's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Keros Therapeutics SG&A Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Jun 23 | Mar 23 | Dec 22 | Mar 22 | Jun 21 | Sep 20 | Mar 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 5 | 4 | 4 | 2 | 10 | 4 | 4 | 3 | 17 | 19 | 16 | 9 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | - | $8.80M | $7.78M | $7.09M | $6.05M | $5.66M | $3.55M | $1.98M |
| Avg Forecast | $306.16K | $364.12K | $433.03K | $514.95K | $-1.56M | $728.23K | $866.05K | $1.03M | $156.05M | $1.46M | $1.73M | $3.89M | $6.69M | $10.14M | $15.21M | $56.18M | $4.99M | $4.68M | $2.93M | $3.90M |
| High Forecast | $306.16K | $364.12K | $433.03K | $514.95K | $-1.56M | $728.23K | $866.05K | $1.03M | $156.05M | $1.46M | $1.73M | $3.89M | $6.69M | $10.14M | $15.21M | $56.18M | $5.99M | $5.62M | $2.93M | $3.90M |
| Low Forecast | $306.16K | $364.12K | $433.03K | $514.95K | $-1.56M | $728.23K | $866.05K | $1.03M | $156.05M | $1.46M | $1.73M | $3.89M | $6.69M | $10.14M | $15.21M | $56.18M | $3.99M | $3.75M | $2.93M | $3.90M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.87% | 0.51% | 0.13% | 1.21% | 1.21% | 1.21% | 0.51% |
Keros Therapeutics's average Quarter SG&A projection for Dec 23 is $6.69M, based on 10 Wall Street analysts, with a range of $6.69M to $6.69M. The forecast indicates a -23.95% fall compared to KROS last annual SG&A of $8.80M (Jun 23).
Keros Therapeutics EPS Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Jun 23 | Mar 23 | Dec 22 | Mar 22 | Jun 21 | Sep 20 | Mar 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 5 | 4 | 4 | 2 | 10 | 4 | 4 | 3 | 17 | 19 | 16 | 9 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | $-1.27 | $-1.15 | $-1.09 | $-1.01 | $-0.67 | $-0.60 | $-0.70 |
| Avg Forecast | $-1.00 | $-1.00 | $-0.99 | $-0.98 | $-1.26 | $-1.25 | $-1.30 | $-1.27 | $-1.22 | $-1.27 | $-1.26 | $-1.33 | $-1.37 | $-1.34 | $-1.12 | $-1.10 | $-0.86 | $-0.66 | $-0.59 | $-0.37 |
| High Forecast | $-1.00 | $-1.00 | $-0.99 | $-0.98 | $-1.26 | $-1.25 | $-1.30 | $-1.27 | $-1.22 | $-1.12 | $-1.26 | $-1.33 | $-1.25 | $-1.34 | $-1.12 | $-1.10 | $-0.86 | $-0.66 | $-0.59 | $-0.37 |
| Low Forecast | $-1.00 | $-1.00 | $-0.99 | $-0.98 | $-1.26 | $-1.25 | $-1.30 | $-1.27 | $-1.22 | $-1.49 | $-1.26 | $-1.33 | $-1.52 | $-1.34 | $-1.12 | $-1.10 | $-0.86 | $-0.66 | $-0.59 | $-0.37 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.95% | 1.02% | 0.99% | 1.17% | 1.02% | 1.01% | 1.89% |
According to undefined Wall Street analysts, Keros Therapeutics's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to KROS previous annual EPS of $NaN (undefined).
Keros Therapeutics Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| KZR | Kezar Life Sciences | $0.57 | $17.50 | 2970.18% | Buy |
| IPSC | Century Therapeutics | $1.60 | $20.00 | 1150.00% | Buy |
| NGM | NGM Biopharmaceuticals | $1.54 | $16.50 | 971.43% | Buy |
| AVTE | Aerovate Therapeutics | $1.90 | $13.00 | 584.21% | Hold |
| FIXX | Q32 Bio | $0.93 | $2.70 | 190.32% | Buy |
| FENC | Fennec Pharmaceuticals | $5.47 | $15.75 | 187.93% | Buy |
| MLYS | Mineralys Therapeutics | $11.76 | $30.00 | 155.10% | Buy |
| EWTX | Edgewise Therapeutics | $18.83 | $48.00 | 154.91% | Buy |
| ERAS | Erasca | $2.97 | $7.00 | 135.69% | Buy |
| REPL | Replimune Group | $11.13 | $24.20 | 117.43% | Buy |
| MGTX | MeiraGTx | $4.25 | $9.00 | 111.76% | Buy |
| LRMR | Larimar Therapeutics | $7.20 | $14.50 | 101.39% | Buy |
| SNDX | Syndax Pharmaceuticals | $19.12 | $36.00 | 88.28% | Buy |
| KROS | Keros Therapeutics | $56.98 | $105.00 | 84.28% | Buy |
| BOLT | Bolt Biotherapeutics | $0.61 | $1.00 | 63.93% | Hold |
| HRMY | Harmony Biosciences | $38.91 | $50.67 | 30.22% | Buy |
| IDYA | IDEAYA Biosciences | $37.46 | $46.13 | 23.14% | Buy |
| JANX | Janux Therapeutics | $50.01 | $59.25 | 18.48% | Buy |
| ANAB | AnaptysBio | $40.33 | $36.33 | -9.92% | Buy |
KROS Forecast FAQ
Is Keros Therapeutics a good buy?
Yes, according to 3 Wall Street analysts, Keros Therapeutics (KROS) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 3 'Buy' recommendations, accounting for 100.00% of KROS's total ratings.
What is KROS's price target?
Keros Therapeutics (KROS) average price target is $105 with a range of $105 to $105, implying a 84.28% from its last price of $56.98. The data is based on 3 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Keros Therapeutics stock go up soon?
According to Wall Street analysts' prediction for KROS stock, the company can go up by 84.28% (from the last price of $56.98 to the average price target of $105), up by 84.28% based on the highest stock price target, and up by 84.28% based on the lowest stock price target.
Can Keros Therapeutics stock reach $90?
KROS's average twelve months analyst stock price target of $105 supports the claim that Keros Therapeutics can reach $90 in the near future.
What are Keros Therapeutics's analysts' financial forecasts?
Keros Therapeutics's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $22.72K (high $22.72K, low $22.72K), average EBITDA is $-4.451K (high $-4.451K, low $-4.451K), average net income is $-184M (high $-184M, low $-184M), average SG&A $1.06M (high $1.06M, low $1.06M), and average EPS is $-5.085 (high $-5.085, low $-5.085). KROS's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $34.57K (high $34.57K, low $34.57K), average EBITDA is $-6.772K (high $-6.772K, low $-6.772K), average net income is $-143M (high $-143M, low $-143M), average SG&A $1.62M (high $1.62M, low $1.62M), and average EPS is $-3.964 (high $-3.964, low $-3.964).
Did the KROS's actual financial results beat the analysts' financial forecasts?
In terms of the last quarterly report (Jun 2021), Keros Therapeutics's revenue was $100K, beating the average analysts' forecast of $100K by 0%. The company's EBITDA was $-15.53M, beating the average prediction of $-15.295M by 1.54%. Keros Therapeutics's net income was $-15.622M, beating the average estimation of $-15.385M by 1.54%. The company's SG&A was $5.66M, beating the average forecast of $4.68M by 20.86%. Lastly, the company's EPS was $-0.67, beating the average prediction of $-0.655 by 2.29%